Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Mr. Richard A. Paulson M.B.A.

President, Chief Executive Officer & Director

Mr. Stuart  Poulton

Executive Vice President & Chief Development Officer

Mr. Michael J. Mano J.D.

Senior Vice President, General Counsel & Secretary

Mr. Cameron  Peters

Vice President of Finance, Assistant Treasurer & Principal Accounting Officer

Dr. Sharon  Shacham M.B.A., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Mr. Michael P. Mason CPA, M.B.A.

Executive Vice President, Chief Financial Officer & Treasurer

Ms. Sohanya  Cheng M.B.A.

Executive Vice President & Chief Commercial Officer

Dr. Mansoor Raza Mirza M.D.

Clinical Consultant, Member of Scientific Advisory Board & Independent Director

Ms. Elhan  Webb C.F.A.

Senior Vice President of Investor Relations

Mr. James  Accumanno J.D.

Chief Compliance Officer

Биотехнологии

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. Структура на управлението

Информация за управлението